- Home
- MCRI vs SNDX Comparison
MCRI vs SNDX Comparison
Compare MCRI & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRI
- SNDX
- Stock Information
- Founded
- MCRI 1972
- SNDX 2005
- Country
- MCRI United States
- SNDX United States
- Employees
- MCRI N/A
- SNDX N/A
- Industry
- MCRI Hotels/Resorts
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- MCRI Consumer Discretionary
- SNDX Health Care
- Exchange
- MCRI Nasdaq
- SNDX Nasdaq
- Market Cap
- MCRI 1.6B
- SNDX 1.3B
- IPO Year
- MCRI 1993
- SNDX 2016
- Fundamental
- Price
- MCRI $97.53
- SNDX $19.91
- Analyst Decision
- MCRI Hold
- SNDX Strong Buy
- Analyst Count
- MCRI 5
- SNDX 12
- Target Price
- MCRI $97.60
- SNDX $36.92
- AVG Volume (30 Days)
- MCRI 96.7K
- SNDX 3.0M
- Earning Date
- MCRI 10-21-2025
- SNDX 11-03-2025
- Dividend Yield
- MCRI 1.23%
- SNDX N/A
- EPS Growth
- MCRI N/A
- SNDX N/A
- EPS
- MCRI 4.41
- SNDX N/A
- Revenue
- MCRI $539,635,000.00
- SNDX $111,304,000.00
- Revenue This Year
- MCRI $6.31
- SNDX $636.61
- Revenue Next Year
- MCRI $4.15
- SNDX $114.95
- P/E Ratio
- MCRI $22.19
- SNDX N/A
- Revenue Growth
- MCRI 4.61
- SNDX 595.65
- 52 Week Low
- MCRI $69.99
- SNDX $8.58
- 52 Week High
- MCRI $113.88
- SNDX $20.08
- Technical
- Relative Strength Index (RSI)
- MCRI 59.71
- SNDX 72.56
- Support Level
- MCRI $94.14
- SNDX $16.75
- Resistance Level
- MCRI $97.51
- SNDX $20.08
- Average True Range (ATR)
- MCRI 2.01
- SNDX 1.23
- MACD
- MCRI 0.61
- SNDX 0.40
- Stochastic Oscillator
- MCRI 78.23
- SNDX 97.58
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.